Industry Symposium by Bracco

IND 19 - The Future is Now: The Novel GBCA Gadopiclenol

Gadolinium-based contrast agents (GBCAs) are fundamental to many diagnostic MRI procedures. However, until recently, most purely extracellular GBCAs had similar relaxivity properties resulting in similar contrast enhancement when administered at equivalent dose. Gadopiclenol is a newly approved, highly stable GBCA with markedly increased relaxivity which permits the administered dose to be halved relative to the approved dose of most other extracellular GBCAs without loss of diagnostic performance. This symposium will address the importance of high relaxivity in clinical practice and will present early clinical experience with gadopiclenol for approved indications in the body and CNS.

2 min
Introduction
Carlo Catalano, Roma / Italy
18 min
The clinical value of high relaxivity
Josef Vymazal, Prague / Czechia
Learning Objectives
To appreciate the value of high relaxivity MR contrast agents in clinical practice.
20 min
Implementation of Gadopiclenol as the extracellular agent for Body MRI Applications
Ali Pirasteh, Madison / United States
Learning Objectives
To learn about the benefits of the newly approved MR contrast agent gadopiclenol for body applications.
20 min
Experience with Gadopiclenol for MRI of the CNS.
Emanuel Kanal, Pittsburgh / United States
Learning Objectives
To learn about the benefits of the newly approved MR contrast agent gadopiclenol for MRI of the CNS.

Lectures

1
Introduction

Introduction

02:00Carlo Catalano, Roma / IT

2
The clinical value of high relaxivity

The clinical value of high relaxivity

18:00Josef Vymazal, Prague / CZ

3
Implementation of Gadopiclenol as the extracellular agent for Body MRI Applications

Implementation of Gadopiclenol as the extracellular agent for Body MRI Applications

20:00Ali Pirasteh, Madison / US

4
Experience with Gadopiclenol for MRI of the CNS.

Experience with Gadopiclenol for MRI of the CNS.

20:00Emanuel Kanal, Pittsburgh / US